Gene expression profiling analysis in nephrology: Towards molecular definition of renal disease

被引：59
作者：
Yasuda Y. [1 ]
Cohen C.D. [1 ]
Henger A. [2 ]
Kretzler M. [2 ]
机构：
[1] Nephrologische Zentrum, Medizinische Poliklinik, Ludwig-Maximilians-Universtaet, D-80336, Munich
[2] Division of Nephrology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI
来源：
Clinical and Experimental Nephrology | 2006年 / 10卷 / 2期
关键词：
cDNA array; Gene expression profiling; Proteomics; Real-time RT-PCR;
D O I：
10.1007/s10157-006-0421-z
中图分类号：
学科分类号：
摘要：
The increase in progressive kidney disease, resulting in a constantly rising prevalence of endstage renal disease (ESRD), urgently warrants the development of more effective strategies to diagnose, prevent, and intervene in renal disease. Histological information obtained by renal biopsies (RBx) is a cornerstone of the current management of kidney disease. Renal tissue can provide critical information on the disease process not available by nontissue-based approaches. However, insight gained by conventional histopathology remains limited and additional strategies to define renal disease on a molecular level are required. The sequencing of the human genome, together with recent advances in genome-wide profiling techniques, has provided the framework for a comprehensive analysis of renal disease-associated transcriptional programs. In this review, strategies to apply these technological advances towards the analysis of RBx will be described, with special emphasis on their potential impact on clinical management, but also on their inherent limitations. Finally, an outlook towards the emerging proteomic studies of renal disease will be given. © Japanese Society of Nephrology 2006.
引用
收藏
页码：91 / 98
页数：7
相关论文
共 80 条
[1]  
Nakai S., Shinzato T., Nagura Y., Masakane I., Kitaoka T., Shinoda T., Et al., Patient Registration Committee, Japanese Society for Dialysis Therapy, Tokyo. An overview of regular dialysis treatment in Japan (as of 31 December 2001), Ther Apher Dial, 8, pp. 3-32, (2004)
[2]  
Barsoum R.S., Chronic kidney disease in the developing world, N Engl J Med, 354, pp. 997-9, (2006)
[3]  
Madaio M.P., Renal biopsy, Kidney Int, 38, pp. 529-43, (1990)
[4]  
Alcorta D.A., Prakash K., Waga I., Sasai H., Munger W., Jennette J.C., Et al., Future molecular approaches to the diagnosis and treatment of glomerular disease, Semin Nephrol, 20, pp. 20-31, (2000)
[5]  
Kretzler M., Cohen C.D., Doran P., Henger A., Madden S., Grone E.F., Et al., Repuncturing the renal biopsy: Strategies for molecular diagnosis in nephrology, J Am Soc Nephrol, 13, pp. 1961-72, (2002)
[6]  
Cohen C.D., Frach K., Schlondorff D., Kretzler M., Quantitative gene expression analysis in renal biopsies: A novel protocol for a high-throughput multicenter application, Kidney Int, 61, pp. 133-40, (2002)
[7]  
Roos-Van Groningen M.C., Eikmans M., Baelde H.J., De Heer E., Bruijn J.A., Improvement of extraction and processing of RNA from renal biopsies, Kidney Int, 65, pp. 97-105, (2004)
[8]  
Suzuki D., Miyazaki M., Naka R., Koji T., Yagame M., Jinde K., Et al., In situ hybridization of interleukin 6 in diabetic nephropathy, Diabetes, 44, pp. 1233-8, (1995)
[9]  
Suzuki D., Miyazaki M., Jinde K., Koji T., Yagame M., Endoh M., Et al., In situ hybridization studies of matrix metalloproteinase-3, tissue inhibitor of metalloproteinase-1 and type IV collagen in diabetic nephropathy, Kidney Int, 52, pp. 111-9, (1997)
[10]  
Toyoda M., Suzuki D., Honma M., Uehara G., Sakai T., Umezono T., Et al., High expression of PKC-MAPK pathway mRNAs correlates with glomerular lesions in human diabetic nephropathy, Kidney Int, 66, pp. 1107-14, (2004)
12345678